State of the Science Summit on Genitourinary Cancers | Conference

Yu Shares Insight on Recent Advances in Castration-Sensitive Prostate Cancer

July 10th 2018

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Localized Bladder Cancer Paradigm Still Faces Obstacles

July 9th 2018

Brock O’Neil, MD, discusses the struggles with treating localized bladder cancer in both the neoadjuvant and adjuvant settings, as well as the advancements with robotic cystectomy.

Expert Elaborates on Emerging Advances in Bladder Cancer Care

July 6th 2018

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Expert Shares Upfront Sequencing Strategies in mRCC

July 6th 2018

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Sequencing Challenges Persist in Metastatic Prostate Cancer

July 5th 2018

Scott Samuelson, MD, discusses frontline treatment of patients with prostate cancer and subsequent sequencing.

Study Could Resolve Abiraterone/Docetaxel Debate in Hormone-Sensitive Prostate Cancer

July 2nd 2018

Andy Hahn, MD, discusses the ongoing debate between abiraterone and docetaxel and the optimal patient selection for each agent in patients with metastatic hormone-sensitive prostate cancer.

Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 25th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer

June 19th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with advanced urothelial cancer.

Agarwal Addresses Sequencing Challenges in Kidney Cancer

June 19th 2018

Neeraj Agarwal, MD, discusses his preferred sequencing strategies for treating patients with kidney cancer, and ongoing immunotherapy research in the field.

Dr. Samuelson on Frontline Treatment and Subsequent Sequencing in Prostate Cancer

June 12th 2018

Scott Samuelson, MD, medical oncologist, Utah Cancer Specialists, on frontline treatment of patients with prostate cancer and subsequent sequencing.

Dr. Grivas on Emerging Biomarkers in Urothelial Cancer

June 5th 2018

Petros Grivas MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program , associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses emerging biomarkers in advanced urothelial cancer.

Dr. Pal on an Enrolling Clinical Trial for Patients With GU Cancers

June 4th 2018

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses an enrolling trial for patients with genitourinary (GU) cancers.

Dr. O'Neil on Adjuvant Therapy in Bladder Cancer

June 1st 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses adjuvant therapy for patients with bladder cancer.

Dr. Hahn on Patient Selection for Abiraterone Versus Docetaxel in mHSPC

May 31st 2018

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Agarwal Discusses Recent FDA Approvals in RCC

May 30th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses recent FDA approvals in renal cell carcinoma.

Dr. Balar Discusses the Impact of Immunotherapy on Bladder Cancer

April 2nd 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of immunotherapy on patients with bladder cancer.

Cytoreductive Nephrectomy Retains Role in Modern RCC Era

March 10th 2018

James Wysock, MD, discusses the evolution of cytoreductive nephrectomy in renal cell carcinoma.

Dr. Wise Discusses Challenges With Immunotherapy in Prostate Cancer

February 22nd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

Dr. Wysock on the Role of Cytoreductive Nephrectomy in RCC

February 15th 2018

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma.

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

February 14th 2018

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).